Arthneeti
RP

Remus Pharmaceuticals Ltd

Q4 FY26Pharmaceuticals & Biotechnology

Remus Pharmaceuticals Ltd Q4 FY26 Results & Presentation Highlights: Revenue, Margins & Order Book

Q4 FY26 investor presentation: what the company reported on revenue, margins and projects.

Price₹942
Market cap₹1.2K Cr
P/E31.2
Updated24 Sept 2026
Read4 min read

Based on Remus Pharmaceuticals Ltd's Q4 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

Quarterly Revenue (H2-FY26): INR 4,534 Mn, up 30.4% YoY from INR 3,478 Mn in H2-FY25 - Operating Expenses (H2-FY26): INR 4,236 Mn, up 31.0% YoY - EBITDA (H2-FY26): INR 298 Mn, up 21.5% YoY - PAT (H2-FY26): INR 246 Mn, up 19.5% YoY - Standalone Revenue (H2-FY26): INR 471 Mn, up 13.5% YoY - Standalone PAT (H2-FY26): INR 127 Mn, up 18.7% YoY - No explicit outlook statement for revenue or volumes is provided in the given presentation excerpts. For H2-FY26 vs H2-FY25 (half yearly, closest quarterly data available): - EBITDA: INR 298 Mn (up 21.5% YoY) - EBITDA Margin: 6.57% (down 47 bps YoY) - PAT: INR 246 Mn (up 19.5% YoY) - PAT Margin: 5.43% (down 49 bps YoY) - The presentation does not explicitly state any margin outlook for the quarter or future periods.

From Remus Pharmaceuticals Ltd's Q4 FY26 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Quarterly Revenue (H2-FY26): INR 4,534 Mn, up 30.4% YoY from INR 3,478 Mn in H2-FY25
  • Operating Expenses (H2-FY26): INR 4,236 Mn, up 31.0% YoY
  • EBITDA (H2-FY26): INR 298 Mn, up 21.5% YoY
  • PAT (H2-FY26): INR 246 Mn, up 19.5% YoY
  • Standalone Revenue (H2-FY26): INR 471 Mn, up 13.5% YoY

2 more points management made on revenue & sales performance

Profitability & Margins

See what Remus Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • FY26 shows Capital Work-In-Progress of INR 83 Mn, indicating ongoing capacity expansion or new project (Page 35).
  • Property, Plant & Equipment increased from INR 21 Mn in FY24 to INR 57 Mn in FY26, suggesting investments in fixed assets (Page 35).
  • No detailed capex amounts, timelines, or plant/project status explicitly mentioned in the presentation.
  • Expansion focus is on strengthening presence via subsidiaries in new countries and launching specialty products (Page 7).

2 more points management made on capital expenditure plans

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1KRM Ayurveda Ltd
Rev 1Mar 1
2Accretion Pharmaceuticals Ltd
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Remus Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation does not explicitly report any figures or details related to order book, order inflow, or pending orders. Based on the provided content: - No mention or data on order book size or value. - No disclosure of order inflow trends or specifics. - No information on pending orders or backlog. The presentation focuses primarily on financials, shareholding, business overview, product registrations, strategic growth plans, and market presence without reference to order-related metrics.

Continue your research

What Remus Pharmaceuticals Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Anuh Pharma Ltd (Q4 FY26)

    202.12 Cr., a 2.50% increase quarter-on-quarter (Page 14) . Key investor presentation takeaways from Anuh Pharma Ltd's Q4 FY26 investor presentation — and how i

  • Themis Medicare Ltd (Q4 FY26)

    Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q4 FY26 inv

  • Lincoln Pharmaceuticals Ltd (Q4 FY26)

    EBITDA: ₹26 crore, a 3% year-on-year increase . Key investor presentation takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how i

  • Kopran Ltd (Q4 FY26)

    6,166 Lakhs increase (~35.8% growth) . Key investor presentation takeaways from Kopran Ltd's Q4 FY26 investor presentation — and how it ranks against sector pee

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Remus Pharmaceuticals Ltd Q4 FY26 results?

Quarterly Revenue (H2-FY26): INR 4,534 Mn, up 30.4% YoY from INR 3,478 Mn in H2-FY25 - Operating Expenses (H2-FY26): INR 4,236 Mn, up 31.0% YoY - EBITDA (H2-FY26): INR 298 Mn, up 21.5% YoY - PAT (H2-FY26): INR 246 Mn, up 19.5% YoY - Standalone Revenue (H2-FY26): INR 471 Mn, up 13.5% YoY - Standalone PAT (H2-FY26): INR 127 Mn, up 18.7% YoY - No explicit outlook statement for revenue or volumes is provided in the given presentation excerpts. For H2-FY26 vs H2-FY25 (half yearly, closest quarterly data available): - EBITDA: INR 298 Mn (up 21.5% YoY) - EBITDA Margin: 6.57% (down 47 bps YoY) - PAT: INR 246 Mn (up 19.5% YoY) - PAT Margin: 5.43% (down 49 bps YoY) - The presentation does not explicitly state any margin outlook for the quarter or future periods.

What is Remus Pharmaceuticals Ltd share price analysis?

Remus Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 31.2 with a market cap of ₹1,154 Cr. Investors should review the full earnings analysis for detailed insights.

Is Remus Pharmaceuticals Ltd planning capital expenditure?

FY26 shows Capital Work-In-Progress of INR 83 Mn, indicating ongoing capacity expansion or new project (Page 35).

Keep Remus Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.